# Index to Volume 144

## Author Index*


**A**

Abe R (*see* Okano et al). 2004;144:183-92
Aberegg SK, Terry PB. Medical decision-making and healthcare disparities: the physician's role. 2004;144:11-17 (Review)
Akira F (*see* Kenichi et al). 2004;144:69-77
Aleksa K, Halachmi N, Ito S, Koren G. Renal ontogeny of ifosfamide nephrotoxicity. 2004;144:285-93
Alvarez M (*see* Sánchez-Campos et al). 2004;144:215-22
Amil J (*see* Montiero et al). 2004;144:319 (Letter)
Araújo F (*see* Montiero et al). 2004;144:319 (Letter)
Aso Y, Takanashi K, Sekine K, Yoshida N, Takebayashi K, Yoshihara K, Inukai T. Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy. 2004;144:92-9
Aung H (*see* Toossi et al). 2004;144:108-15

**B**

Baía F (*see* Montiero et al). 2004;144:319 (Letter)
Beeh K-M (*see* Beier et al). 2004;144:39-44
Beier J, Beeh K-M, Kornmann O, Buhl R. Induced sputum methodology: validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals. 2004;144:39-44
Beutler E, Beutler L, West C. Mutations in the gene encoding cytosolic β-glucosidase in Gaucher disease. 2004;144:65-8
Beutler L (*see* Beutler et al). 2004;144:65-8
Biesma DH (*see* Schutgens et al). 2004;144:100-7
Bouter PK (*see* Bouwman et al). 2004;144:18-26
Bouwman JJM, Visseren FLJ, Bouter PK, Diepersloot RJA. Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and *Chlamydia pneumoniae*. 2004;144:18-26
Brodin E, Svensson B, Paulssen RH, Nordoy A, Hansen J-B. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment. 2004;144:246-53
Buhl R (*see* Beier et al). 2004;144:39-44
Buonocore G (*see* Di Guiseppe et al). 2004;144:235-46

**C**

Camicioli R (*see* MacIntyre et al). 2004;144:294-301
Capecchi PL (*see* Di Guiseppe et al). 2004;144:235-46
Casonato A, Cattini MG, Soldera C, Marcato S, Sartorello F, Pontara E, Pagnan A. A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function. 2004;144:254-9
Cattini MG (*see* Casonato et al). 2004;144:254-9
Cellesi C (*see* Di Guiseppe et al). 2004;144:235-46
Cheng EY (*see* Skubitz et al). 2004;144:193-200
Cheng TO. Lind's SCURVY trial. 2004;144:53 (Letter)
Cheung AK (*see* Kim et al). 2004;144:156-62
Chevailler A (*see* Sanmarco et al). 2004;144:141-7
Clohisy DR (*see* Skubitz et al). 2004;144:193-200
Cohen J-H M (*see* Sanmarco et al). 2004;144:141-7
Corazza GR (*see* Di Stefano et al). 2004;144:313-8
Cox DW (*see* MacIntyre et al). 2004;144:294-301
Culebras JM (*see* Sánchez-Campos et al). 2004;144:215-22

**D**

Del Pozo R (*see* Jüngst et al). 2004;144:134-40
Di Guiseppe D, Frosali S, Priora R, Di Simplicio FC, Buonocore G, Cellesi C, Capecchi PL, Pasini FL, Lazzerini PE, Jakubowski H, Di Simplicio P. The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols. 2004;144:235-46
Di Simplicio FC (*see* Di Guiseppe et al). 2004;144:235-46
Di Simplicio P (*see* Di Guiseppe et al). 2004;144:235-46
Di Stefano M, Missanelli A, Miceli E, Strocchi A, Corazza GR. Hydrogen breath test in the diagnosis of lactose malabsorption: Accuracy of new *versus* conventional criteria. 2004;144:313-8
Diepersloot RJA (*see* Bouwman et al). 2004;144:18-26

**E**

Eckman JR (*see* Wagner et al). 2004;144:260-7
Eguchi K (*see* Hida et al). 2004;144:148-55
Escande A (*see* Sanmarco et al). 2004;144:141-7
Esseboom EU (*see* Schutgens et al). 2004;144:100-7

**F**

Fischer S (*see* Jüngst et al). 2004;144:134-40
Foley TP (*see* Hofman et al). 2004;144:307-12
Freel RW (*see* Harris et al). 2004;144:45-52
Frosali S (*see* Di Guiseppe et al). 2004;144:235-46
Fu P (*see* Yin et al). 2004;144:302-6

**G**

Garner HP. Peroxidase activity within circulating neutrophils correlates with pulmonary phenotype in cystic fibrosis. 2004;144:127-33
Gauthier T (*see* Kuvibidila et al). 2004;144:176-82
Gayet S (*see* Sanmarco et al). 2004;144:141-7
Ghosh AK. On the challenges of using evidence-based information: the role of clinical uncertainty. 2004;144:60-4 (Review)
Goetz J (*see* Sanmarco et al). 2004;144:141-7
Gonzalez-Gallego J (*see* Sánchez-Campos et al). 2004;144:215-22
Gussmann E (*see* Jüngst et al). 2004;144:134-40
Gutfreund KS (*see* MacIntyre et al). 2004;144:294-301

**H**

Haas FJLM (*see* Schutgens et al). 2004;144:100-7
Habiro K (*see* Okano et al). 2004;144:183-92
Hahn BL (*see* Lulloff et al). 2004;144:208-14
Halachmi N (*see* Aleksa et al). 2004;144:285-93
Hammerschmidt DE. A new look and a heightened focus: translational medicine and the *Journal of Laboratory and Clinical Medicine*. 2004;144:5-6 (Editorial)
Hammerschmidt DE. CT angiogram: multiple small pulmonary emboli. 2004;144:116 (About the cover)


*July, pp. 1-54; August, pp. 55-116; September, pp. 117-168; October, pp. 169-224; November, pp. 225-276; December, pp. 277-334.

# Index to Volume 144

## Author Index*


**A**

Abe R (*see* Okano et al). 2004;144:183-92
Aberegg SK, Terry PB. Medical decision-making and healthcare disparities: the physician's role. 2004;144:11-17 (Review)
Akira F (*see* Kenichi et al). 2004;144:69-77
Aleksa K, Halachmi N, Ito S, Koren G. Renal ontogeny of ifosfamide nephrotoxicity. 2004;144:285-93
Alvarez M (*see* Sánchez-Campos et al). 2004;144:215-22
Amil J (*see* Montiero et al). 2004;144:319 (Letter)
Araújo F (*see* Montiero et al). 2004;144:319 (Letter)
Aso Y, Takanashi K, Sekine K, Yoshida N, Takebayashi K, Yoshihara K, Inukai T. Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy. 2004;144:92-9
Aung H (*see* Toossi et al). 2004;144:108-15

**B**

Baía F (*see* Montiero et al). 2004;144:319 (Letter)
Beeh K-M (*see* Beier et al). 2004;144:39-44
Beier J, Beeh K-M, Kornmann O, Buhl R. Induced sputum methodology: validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals. 2004;144:39-44
Beutler E, Beutler L, West C. Mutations in the gene encoding cytosolic β-glucosidase in Gaucher disease. 2004;144:65-8
Beutler L (*see* Beutler et al). 2004;144:65-8
Biesma DH (*see* Schutgens et al). 2004;144:100-7
Bouter PK (*see* Bouwman et al). 2004;144:18-26
Bouwman JJM, Visseren FLJ, Bouter PK, Diepersloot RJA. Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and *Chlamydia pneumoniae*. 2004;144:18-26
Brodin E, Svensson B, Paulssen RH, Nordoy A, Hansen J-B. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment. 2004;144:246-53
Buhl R (*see* Beier et al). 2004;144:39-44
Buonocore G (*see* Di Guiseppe et al). 2004;144:235-46

**C**

Camicioli R (*see* MacIntyre et al). 2004;144:294-301
Capecchi PL (*see* Di Guiseppe et al). 2004;144:235-46
Casonato A, Cattini MG, Soldera C, Marcato S, Sartorello F, Pontara E, Pagnan A. A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function. 2004;144:254-9
Cattini MG (*see* Casonato et al). 2004;144:254-9
Cellesi C (*see* Di Guiseppe et al). 2004;144:235-46
Cheng EY (*see* Skubitz et al). 2004;144:193-200
Cheng TO. Lind's SCURVY trial. 2004;144:53 (Letter)
Cheung AK (*see* Kim et al). 2004;144:156-62
Chevailler A (*see* Sanmarco et al). 2004;144:141-7
Clohisy DR (*see* Skubitz et al). 2004;144:193-200
Cohen J-H M (*see* Sanmarco et al). 2004;144:141-7
Corazza GR (*see* Di Stefano et al). 2004;144:313-8
Cox DW (*see* MacIntyre et al). 2004;144:294-301
Culebras JM (*see* Sánchez-Campos et al). 2004;144:215-22

**D**

Del Pozo R (*see* Jüngst et al). 2004;144:134-40
Di Guiseppe D, Frosali S, Priora R, Di Simplicio FC, Buonocore G, Cellesi C, Capecchi PL, Pasini FL, Lazzerini PE, Jakubowski H, Di Simplicio P. The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols. 2004;144:235-46
Di Simplicio FC (*see* Di Guiseppe et al). 2004;144:235-46
Di Simplicio P (*see* Di Guiseppe et al). 2004;144:235-46
Di Stefano M, Missanelli A, Miceli E, Strocchi A, Corazza GR. Hydrogen breath test in the diagnosis of lactose malabsorption: Accuracy of new *versus* conventional criteria. 2004;144:313-8
Diepersloot RJA (*see* Bouwman et al). 2004;144:18-26

**E**

Eckman JR (*see* Wagner et al). 2004;144:260-7
Eguchi K (*see* Hida et al). 2004;144:148-55
Escande A (*see* Sanmarco et al). 2004;144:141-7
Esseboom EU (*see* Schutgens et al). 2004;144:100-7

**F**

Fischer S (*see* Jüngst et al). 2004;144:134-40
Foley TP (*see* Hofman et al). 2004;144:307-12
Freel RW (*see* Harris et al). 2004;144:45-52
Frosali S (*see* Di Guiseppe et al). 2004;144:235-46
Fu P (*see* Yin et al). 2004;144:302-6

**G**

Garner HP. Peroxidase activity within circulating neutrophils correlates with pulmonary phenotype in cystic fibrosis. 2004;144:127-33
Gauthier T (*see* Kuvibidila et al). 2004;144:176-82
Gayet S (*see* Sanmarco et al). 2004;144:141-7
Ghosh AK. On the challenges of using evidence-based information: the role of clinical uncertainty. 2004;144:60-4 (Review)
Goetz J (*see* Sanmarco et al). 2004;144:141-7
Gonzalez-Gallego J (*see* Sánchez-Campos et al). 2004;144:215-22
Gussmann E (*see* Jüngst et al). 2004;144:134-40
Gutfreund KS (*see* MacIntyre et al). 2004;144:294-301

**H**

Haas FJLM (*see* Schutgens et al). 2004;144:100-7
Habiro K (*see* Okano et al). 2004;144:183-92
Hahn BL (*see* Lulloff et al). 2004;144:208-14
Halachmi N (*see* Aleksa et al). 2004;144:285-93
Hammerschmidt DE. A new look and a heightened focus: translational medicine and the *Journal of Laboratory and Clinical Medicine*. 2004;144:5-6 (Editorial)
Hammerschmidt DE. CT angiogram: multiple small pulmonary emboli. 2004;144:116 (About the cover)


*July, pp. 1-54; August, pp. 55-116; September, pp. 117-168; October, pp. 169-224; November, pp. 225-276; December, pp. 277-334.

Hammerschmidt DE. Donald G. Walker, MD: parabiosis and the pathobiology of osteopetrosis. 2004;144:223-4 (About the cover)
Hammerschmidt DE. Dr. Jay McLean—one of the discoverers of heparin. 2004;144:273-4 (About the cover)
Hammerschmidt DE. Odysseus and the sirens. 2004;144:54 (About the cover)
Hammerschmidt DE. Recruiting for a clinical study (disparities in health care and research). 2004;144:167-8 (About the cover)
Hammerschmidt DE. The adventures of Freiherr von Münchhausen. 2004;144:320-1 (About the cover)
Hammerschmidt DE. This month in J Lab Clin Med. 2004;144:1-3, 117-20, 144:55-7, 169-72, 225-8, 277-9
Hansen J-B (*see* Brodin et al). 2004;144:246-53
Hara K, Hirowatari Y, Yoshika M, Komiyama Y, Tsuka Y, Takahashi H. The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease. 2004;144:31-7
Harris AH, Freel RW, Hatch M. Serum oxalate in human beings and rats as determined with the use of ion chromatography. 2004;144:45-52
Hatch M (*see* Harris et al). 2004;144:45-52
Hejal R (*see* Toossi et al). 2004;144:108-15
Henriques E (*see* Montiero et al). 2004;144:319 (Letter)
Henry JJ (*see* Hofman et al). 2004;144:307-12
Herron JG (*see* Garner et al). 2004;144:127-33
Hida A, Kawakami A, Miyashita T, Yamasaki S, Nakashima K, Tanaka F, Izumi Y, Tamai M, Huang M, Ida H, Nakamura H, Origuchi T, Ueki Y, Eguchi K. Nitric oxide acts on the mitochondria and protects human endothelial cells from apoptosis. 2004;144:148-55
Hirowatari Y (*see* Hara et al). 2004;144:31-7
Hofman LF, Foley TP, Henry JJ, Naylor EW. The use of filter paper–dried blood spots for thyroid-antibody screening in adults. 2004;144:307-12
Holzer G (*see* Lang et al). 2004;144:163-6
Horita S (*see* Okano et al). 2004;144:183-92
Huang M (*see* Hida et al). 2004;144:148-55
Humbel R-L (*see* Sanmarco et al). 2004;144:141-7

## I

Ida H (*see* Hida et al). 2004;144:148-55
Inukai T (*see* Aso et al). 2004;144:92-9
Islam N (*see* Toossi et al). 2004;144:108-15
Ito S (*see* Aleksa et al). 2004;144:285-93
Izumi Y (*see* Hida et al). 2004;144:148-55

## J

Jakubowski H (*see* Di Guiseppe et al). 2004;144:235-46
Jin G (*see* Yin et al). 2004;144:302-6
Johanet C (*see* Sanmarco et al). 2004;144:141-7
Jokinen CH, Swaim WR, Nuttall FQ. A case of hereditary xerocytosis diagnosed as a result of suspected hypoglycemia and observed low glycohemoglobin. 2004;144:27-30
Jüngst C (*see* Jüngst et al). 2004;144:134-40
Jüngst D, Gussmann E, Zündt B, Meyer G, Jüngst C, Del Pozo R, Fischer S. Solubility of cholesterol in the crystal-free gallbladder bile of gallstone patients. 2004;144:134-40

## K

Kamerath CD (*see* Kim et al). 2004;144:156-62
Katsushige A (*see* Kenichi et al). 2004;144:69-77
Kawakami A (*see* Hida et al). 2004;144:148-55
Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, Takashi H, Yoshiyuki O, Shigeru K. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting–enzyme inhibitor. 2004;144:69-77
Kim S-J, Masaki T, Leypoldt JK, Kamerath CD, Mohammad SF, Cheung AK. Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs. 2004;144:156-62
Komiyama Y (*see* Hara et al). 2004;144:31-7
Koren G (*see* Aleksa et al). 2004;144:285-93
Kornmann O (*see* Beier et al). 2004;144:39-44
Kuvibidila S, Gauthier T, Warrier RP, Rayford W. Increased levels of serum transferrin receptor and serum transferrin receptor/log ferritin ratios in men with prostate cancer and the implications for body-iron stores. 2004;144:176-82

## L

Lang T, Willinger U, Holzer G. Soluble cathepsin-L: a marker of bone resorption and bone density? 2004;144:163-6
Lazzerini PE (*see* Di Guiseppe et al). 2004;144:235-46
Leypoldt JK (*see* Kim et al). 2004;144:156-62
Lisman T (*see* Schutgens et al). 2004;144:100-7
Lulloff SJ, Hahn BL, Sohnle PG. Fungal susceptibility to zinc deprivation. 2004;144:208-14

## M

MacIntyre G, Gutfreund KS, Martin WRW, Camicioli R, Cox DW. Value of an enzymatic assay for the determination of serum ceruloplasmin. 2004;144:294-301
Marcato S (*see* Casonato et al). 2004;144:254-9
Martin WRW (*see* MacIntyre et al). 2004;144:294-301
Masaki T (*see* Kim et al). 2004;144:156-62
Masanobu M (*see* Kenichi et al). 2004;144:69-77
Meslin EM, Quaid KA. Ethical issues in the collection, storage, and research use of human biological materials. 2004;144:229-34 (Review)
Meyer G (*see* Jüngst et al). 2004;144:134-40
Meyer KC. Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good. 2004;144:124-6 (Editorial)
Miceli E (*see* Di Stefano et al). 2004;144:313-8
Milla CE (*see* Garner et al). 2004;144:127-33
Missanelli A (*see* Di Stefano et al). 2004;144:313-8
Miyashita T (*see* Hida et al). 2004;144:148-55
Mohammad SF (*see* Kim et al). 2004;144:156-62
Montiero C, Trindade E, Montiero F, Henriques E, Baía F, Amil J, Araújo F. Blood group–antigen profile predicted by molecular biology in Munchausen syndrome by proxy. 2004;144:319 (Letter)
Montiero F (*see* Montiero et al). 2004;144:319 (Letter)

## N

Nakamura H (*see* Hida et al). 2004;144:148-55
Nakashima K (*see* Hida et al). 2004;144:148-55
Naylor EW (*see* Hofman et al). 2004;144:307-12
Nieuwenhuis HK (*see* Schutgens et al). 2004;144:100-7
Nihei H (*see* Okano et al). 2004;144:183-92
Nitta K (*see* Okano et al). 2004;144:183-92
Nordoy A (*see* Brodin et al). 2004;144:246-53
Nuttall FQ (*see* Jokinen et al). 2004;144:27-30

## O

Ogawa S (*see* Okano et al). 2004;144:183-92
Okano K, Nitta K, Ogawa S, Horita S, Habiro K, Nihei H, Abe R. Effects of double blockade of CD28 and inducible-costimulator signaling on anti–glomerular basement membrane glomerulonephritis. 2004;144:183-92

Oksman F (*see* Sanmarco et al). 2004;144:141-7
Origuchi T (*see* Hida et al). 2004;144:148-55

**P**

Pagnan A (*see* Casonato et al). 2004;144:254-9
Pamplona R, Portero-Otin M. Advanced glycation end products in urine: Are some sugar-derived products better than others? 2004; 144:58-9 (Editorial)
Pasini FL (*see* Di Guiseppe et al). 2004;144:235-46
Paulssen RH (*see* Brodin et al). 2004;144:246-53
Phillips JR (*see* Garner et al). 2004;144:127-33
Pierach CA. Did Ulysses have porphyria? 2004;144:7-10 (Review)
Pontara E (*see* Casonato et al). 2004;144:254-9
Portero-Otin M (*see* Pamplona and Portero-Otin). 2004;144:58-9 (Editorial)
Priora R (*see* Di Guiseppe et al). 2004;144:235-46

**Q**

Quaid KA (*see* Meslin and Quaid). 2004;144:229-34 (Review)

**R**

Rayford W (*see* Kuvibidila et al). 2004;144:176-82
Regelmann WE (*see* Garner et al). 2004;144:127-33
Richardson DR. Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer. 2004;144:173-5 (Editorial)
Roll P (*see* Sanmarco et al). 2004;144:141-7

**S**

Sánchez-Campos S, Alvarez M, Culebras JM, Gonzalez-Gallego J, Tuñón MJ. Pathogenic molecular mechanisms in an animal model of fulminant hepatic failure: rabbit hemorrhagic viral disease. 2004;144:215-22
Sanmarco M, Roll P, Gayet S, Oksman F, Escande A, Cohen J-H M, Chevailler A, Goetz J, Humbel R-L, Sibilia J. Combined search for anti–ß2-glycoprotein i and anticardiolipin antibodies in antiphospholipid syndrome: contribution to diagnosis. 2004;144: 141-7
Sartorello F (*see* Casonato et al). 2004;144:254-9
Schilling RF. Intrinsic factor studies: II. the effect of gastric juice on the urinary excretion of radioactivity after the oral administration of radioactive vitamin $B_{12}$. 2004;144:268-72 (Landmark article)
Schutgens REG, Esseboom EU, Snijder RJ, Haas FJLM, Verzijlbergen F, Nieuwenhuis HK, Lisman T, Biesma DH. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. 2004; 144:100-7
Sekine K (*see* Aso et al). 2004;144:92-9
Severson SJ (*see* Garner et al). 2004;144:127-33
Shigeru K (*see* Kenichi et al). 2004;144:69-77
Shoko T (*see* Kenichi et al). 2004;144:69-77
Sibilia J (*see* Sanmarco et al). 2004;144:141-7
Skubitz APN (*see* Skubitz and Skubitz). 2004;144:78-91
Skubitz APN (*see* Skubitz et al). 2004;144:193-200
Skubitz KM, Cheng EY, Clohisy DR, Thompson RC, Skubitz APN. Gene expression in giant-cell tumors. 2004;144:193-200
Skubitz KM, Skubitz APN. Characterization of sarcomas by means of gene expression. 2004;144:78-91
Snijder RJ (*see* Schutgens et al). 2004;144:100-7
Sohnle PG (*see* Lulloff et al). 2004;144:208-14
Soldera C (*see* Casonato et al). 2004,144:254-9
Strocchi A (*see* Di Stefano et al). 2004;144:313-8
Sullivan JL. Is stored iron safe?. 2004;144:280-4 (Review)
Svensson B (*see* Brodin et al). 2004;144:246-53
Swaim WR (*see* Jokinen et al). 2004;144:27-30

**T**

Takahashi H (*see* Hara et al). 2004;144:31-7
Takanashi K (*see* Aso et al). 2004;144:92-9
Takashi H (*see* Kenichi et al). 2004;144:69-77
Takebayashi K (*see* Aso et al). 2004;144:92-9
Takehiko K (*see* Kenichi et al). 2004;144:69-77
Tamai M (*see* Hida et al). 2004;144:148-55
Tanaka F (*see* Hida et al). 2004;144:148-55
Tanaka R (*see* Yoshida and Tanaka). 2004;144:201-7
Teixeira-Johnson L (*see* Toossi et al). 2004;144:108-15
Terry PB (*see* Aberegg and Terry). 2004;144:11-17 (Review)
Thompson RC (*see* Skubitz et al). 2004;144:193-200
Toossi Z, Wu M, Islam N, Teixeira-Johnson L, Hejal R, Aung H. Transactivation of human immunodeficiency virus-1 in T-cells by *Mycobacterium tuberculosis*-infected mononuclear phagocytes. 2004;144:108-15
Trindade E (*see* Montiero et al). 2004;144:319 (Letter)
Tsuka Y (*see* Hara et al). 2004;144:31-7
Tuñón MJ (*see* Sánchez-Campos et al). 2004;144:215-22

**U**

Ueki Y (*see* Hida et al). 2004;144:148-55

**V**

van Erpecum KJ. Cholesterol-gallstone formation: more than a biliary lipid defect? 2004;144:121-3 (Editorial)
Verzijlbergen F (*see* Schutgens et al). 2004;144:100-7
Visseren FLJ (*see* Bouwman et al). 2004;144:18-26

**W**

Wagner MC, Eckman JR, Wick TM. Sickle cell adhesion depends on hemodynamics and endothelial activation. 2004;144:260-7
Wang X (*see* Yin et al). 2004;144:302-6
Warrier RP (*see* Kuvibidila et al). 2004;144:176-82
West C (*see* Beutler et al). 2004;144:65-8
Wick TM (*see* Wagner et al). 2004;144:260-7
Willinger U (*see* Lang et al). 2004;144:163-6
Wu M (*see* Toossi et al). 2004;144:108-15

**X**

Xiu R (*see* Yin et al). 2004;144:302-6

**Y**

Yamasaki S (*see* Hida et al). 2004;144:148-55
Yin J, Fu P, Wang X, Jin G, Xiu R. Tumor-specific expression detected with the use of an expression vector driven by human telomerase reverse transcriptase gene promoter. 2004;144:302-6
Yoshida N (*see* Aso et al). 2004;144:92-9
Yoshida S, Tanaka R. Generation of a human leukocyte antigen-A24–restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors. 2004; 144:201-7
Yoshihara K (*see* Aso et al). 2004;144:92-9
Yoshika M (*see* Hara et al). 2004;144:31-7
Yoshiyuki O (*see* Kenichi et al). 2004;144:69-77

**Z**

Zündt B (*see* Jüngst et al). 2004;144:134-40

# Index to Volume 144

## Subject Index*


A

**Anemia, iron-deficiency**
Is stored iron safe? (Sullivan). 2004;144:280-4 (Review)

**Anemia, sickle cell**
Sickle cell adhesion depends on hemodynamics and endothelial activation (Wagner et al). 2004;144:260-7
Sickle cell disease: What makes the red cells stay in the microvasculature long enough to sickle? (Hammerschmidt). 2004; 144:227-8 (This month in J Lab Clin Med)

**Angiotensin-converting enzyme inhibitors**
Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting–enzyme inhibitor (Kenichi et al). 2004;144:69-77

**Antibiotics**
Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and *Chlamydia pneumoniae* (Bouwman et al). 2004;144:18-26
Secondary effects of macrolide antibiotics: Sometimes they work for the reasons we'd guess (Hammerschmidt). 2004;144:2-3 (This month in J Lab Clin Med)

**Anticoagulants**
CT angiogram: multiple small pulmonary emboli (Hammerschmidt). 2004;144:116 (About the cover)
Dr. Jay McLean—one of the discoverers of heparin (Hammerschmidt). 2004;144:273-4 (About the cover)
Low molecular weight heparin: a closer look at its anticoagulant effect (Hammerschmidt). 2004;144:56-7 (This month in J Lab Clin Med)
Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism (Schutgens et al). 2004;144:100-7

**Antigens, CD28**
Effects of double blockade of CD28 and inducible-costimulator signaling on anti–glomerular basement membrane glomerulonephritis (Okano et al). 2004;144:183-92

**Antiphospholipid syndrome**
Antiphospholipid antibodies: from the trivial to the treacherous (Hammerschmidt). 2004;144:117-18 (This month in J Lab Clin Med)
Combined search for anti–ß2-glycoprotein i and anticardiolipin antibodies in antiphospholipid syndrome: contribution to diagnosis (Sanmarco et al). 2004;144:141-7

**Apoptosis**
Nitric oxide acts on the mitochondria and protects human endothelial cells from apoptosis (Hida et al). 2004;144:148-55

**Arthritis, rheumatoid**
Nitric oxide acts on the mitochondria and protects human endothelial cells from apoptosis (Hida et al). 2004;144:148-55
Rheumatoid pannus: What is nitric oxide doing there? (Hammerschmidt). 2004;144:119-20 (This month in J Lab Clin Med)

**Ascorbic acid**
Lind's SCURVY trial (Cheng) (Letter). 2004;144:53

**Asthma**
Induced sputum methodology: validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals (Beier et al). 2004;144:39-44

**Atherosclerosis;** *see* Cardiovascular diseases

B

**Beta-glucosidase**
Mutations in the gene encoding cytosolic β-glucosidase in Gaucher disease (Beutler et al). 2004;144:65-8

**Bias**
Medical decision-making and healthcare disparities: the physician's role (Aberegg and Terry). 2004;144:11-17 (Review)

**Bile**
Cholesterol-gallstone formation: more than a biliary lipid defect? (van Erpecum). 2004;144:121-3 (Editorial)
Solubility of cholesterol in the crystal-free gallbladder bile of gallstone patients (Jüngst et al). 2004;144:134-40

**Bone density**
Osteoclast enzymes and bone density: Can serum assays provide useful clinical information? (Hammerschmidt). 2004;144:118 (This month in J Lab Clin Med)
Soluble cathepsin-L: a marker of bone resorption and bone density? (Lang et al). 2004;144:163-6

**Bronchiectasis**
Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good (Meyer). 2004;144:124-6 (Editorial)

C

**Candidiasis**
Fungal susceptibility to zinc deprivation (Lulloff et al). 2004;144: 208-14
Metallic cations and fungal growth (Hammerschmidt). 2004;144: 170 (This month in J Lab Clin Med)

**Cardiolipins**
Antiphospholipid antibodies: from the trivial to the treacherous (Hammerschmidt). 2004;144:117-18 (This month in J Lab Clin Med)
Combined search for anti–ß2-glycoprotein i and anticardiolipin antibodies in antiphospholipid syndrome: contribution to diagnosis (Sanmarco et al). 2004;144:141-7

**Cardiovascular diseases;** *see also* Vascular diseases
Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and *Chlamydia pneumoniae* (Bouwman et al). 2004;144:18-26
The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols (Di Guiseppe et al). 2004;144:235-46
The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease (Hara et al). 2004;144:31-7


*July, pp. 1-54; August, pp. 55-116; September, pp. 117-168; October, pp. 169-224; November, pp. 225-276; December, pp. 277-334.

**Cathepsin L**

Osteoclast enzymes and bone density: Can serum assays provide useful clinical information? (Hammerschmidt). 2004;144:118 (This month in J Lab Clin Med)

Soluble cathepsin-L: a marker of bone resorption and bone density? (Lang et al). 2004;144:163-6

**Catheters, indwelling**

Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs (Kim et al). 2004;144:156-62

Maintaining function of vascular-access catheters: Different vascular sites may require different strategies (Hammerschmidt). 2004;144:118-19 (This month in J Lab Clin Med)

**CD 28;** *see* Antigens, CD28

**Ceruloplasmin**

Measuring ceruloplasmin (Hammerschmidt). 2004;144:279 (This month in J Lab Clin Med)

Value of an enzymatic assay for the determination of serum ceruloplasmin (MacIntyre et al). 2004;144:294-301

**Child abuse**

Blood group–antigen profile predicted by molecular biology in Munchausen syndrome by proxy (Montiero et al) (Letter). 2004;144:319

Sick babies, doping athletes, and Baron von Münchhausen: Whose blood is it, anyway? (Hammerschmidt). 2004;144: 278-9 (This month in J Lab Clin Med)

**Cholesterol**

Cholesterol-gallstone formation: more than a biliary lipid defect? (van Erpecum). 2004;144:121-3 (Editorial)

Solubility of cholesterol in the crystal-free gallbladder bile of gallstone patients (Jüngst et al). 2004;144:134-40

**Chromatography**

Serum oxalate in human beings and rats as determined with the use of ion chromatography (Harris et al). 2004;144:45-52

**Coagulation;** *see also* Anticoagulants; Platelets

Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment (Brodin et al). 2004; 144:246-53

**Correspondence;** *see* Letters to the editor

**Cystic fibrosis**

Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good (Meyer). 2004;144:124-6 (Editorial)

Peroxidase activity within circulating neutrophils correlates with pulmonary phenotype in cystic fibrosis (Garner). 2004;144: 127-33

**D**

**Decision making**

On the challenges of using evidence-based information: the role of clinical uncertainty (Ghosh). 2004;144:60-4 (Review)

Evidence-based medicine: What do you do when the evidence is lacking? An essay in translational medicine (Hammerschmidt). 2004;144:55-6 (This month in J Lab Clin Med)

Medical decision-making and healthcare disparities: the physician's role (Aberegg and Terry). 2004;144:11-17 (Review)

**Dendritic cells**

Generation of a human leukocyte antigen-A24–restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors (Yoshida and Tanaka). 2004;144:201-7

**Diabetes mellitus**

Advanced glycation end products in urine: Are some sugar-derived products better than others? (Pamplona and Portero-Otin). 2004;144:58-9 (Editorial)

Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy (Aso et al). 2004;144:92-9

Glycation products in diabetic urine—What do they mean? (Hammerschmidt). 2004;144:57 (This month in J Lab Clin Med)

Glycosylated hemoglobin and erythrocyte survival (Hammerschmidt). 2004;144:1-2 (This month in J Lab Clin Med)

Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting–enzyme inhibitor (Kenichi et al). 2004;144:69-77

**Diagnosis**

Did Ulysses have porphyria? (Pierach). 2004;144:7-10 (Review)

Odysseus and the sirens (Hammerschmidt). 2004;144:54 (About the cover)

**Drug toxicity**

Alkylators and the kidney: Why are small children more vulnerable to renal damage? (Hammerschmidt). 2004;144:278 (This month in J Lab Clin Med)

Renal ontogeny of ifosfamide nephrotoxicity (Aleksa et al). 2004; 144:285-93

**E**

**Editorials**

Advanced glycation end products in urine: Are some sugar-derived products better than others? (Pamplona and Portero-Otin). 2004;144:58-9 (Editorial)

Cholesterol-gallstone formation: more than a biliary lipid defect? (van Erpecum). 2004;144:121-3 (Editorial)

Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer (Richardson). 2004;144:173-5 (Editorial)

Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good (Meyer). 2004;144:124-6 (Editorial)

A new look and a heightened focus: translational medicine and the *Journal of Laboratory and Clinical Medicine* (Hammerschmidt). 2004;144:5-6 (Editorial)

**Endothelium, vascular**

Sickle cell adhesion depends on hemodynamics and endothelial activation (Wagner et al). 2004;144:260-7

**Erythrocytes**

A case of hereditary xerocytosis diagnosed as a result of suspected hypoglycemia and observed low glycohemoglobin (Jokinen et al). 2004;144:27-30

Glycosylated hemoglobin and erythrocyte survival (Hammerschmidt). 2004;144:1-2 (This month in J Lab Clin Med)

Sickle cell adhesion depends on hemodynamics and endothelial activation (Wagner et al). 2004;144:260-7

Sickle cell disease: What makes the red cells stay in the microvasculature long enough to sickle? (Hammerschmidt). 2004; 144:227-8 (This month in J Lab Clin Med)

**Ethics**

Challenges in translational medicine: the changing face of research ethics (Hammerschmidt). 2004;144:226 (This month in J Lab Clin Med)

Ethical issues in the collection, storage, and research use of human biological materials (Meslin and Quaid). 2004;144: 229-34 (Review)

Recruiting for a clinical study (disparities in health care and research) (Hammerschmidt). 2004;144:167-8 (About the cover)

**Evidence-based medicine**

On the challenges of using evidence-based information: the role of clinical uncertainty (Ghosh). 2004;144:60-4 (Review)

Evidence-based medicine: What do you do when the evidence is lacking? An essay in translational medicine (Hammerschmidt). 2004;144:55-6 (This month in J Lab Clin Med)

F

**Ferritin**

Increased levels of serum transferrin receptor and serum transferrin receptor/log ferritin ratios in men with prostate cancer and the implications for body-iron stores (Kuvibidila et al). 2004;144:176-82

Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer (Richardson). 2004;144:173-5 (Editorial)

**Fungi**

Fungal susceptibility to zinc deprivation (Lulloff et al). 2004;144:208-14

Metallic cations and fungal growth (Hammerschmidt). 2004;144:170 (This month in J Lab Clin Med)

G

**Gallstones**

Cholesterol-gallstone formation: more than a biliary lipid defect? (van Erpecum). 2004;144:121-3 (Editorial)

Solubility of cholesterol in the crystal-free gallbladder bile of gallstone patients (Jüngst et al). 2004;144:134-40

**Gaucher disease**

Mutations in the gene encoding cytosolic $\beta$-glucosidase in Gaucher disease (Beutler et al). 2004;144:65-8

**Gene expression**

Characterization of sarcomas by means of gene expression (Skubitz and Skubitz). 2004;144:78-91

Gene expression in giant-cell tumors (Skubitz et al). 2004;144:193-200

Homing in on the genes involved in malignant transformation: giant-cell tumors (Hammerschmidt). 2004;144:171 (This month in J Lab Clin Med)

Tumor-specific expression detected with the use of an expression vector driven by human telomerase reverse transcriptase gene promoter (Yin et al). 2004;144:302-6

**Gene therapy**

Gene therapy: Can we make it more selective? (Hammerschmidt). 2004;144:277 (This month in J Lab Clin Med)

Tumor-specific expression detected with the use of an expression vector driven by human telomerase reverse transcriptase gene promoter (Yin et al). 2004;144:302-6

**Giant cell tumors**

Gene expression in giant-cell tumors (Skubitz et al). 2004;144:193-200

Homing in on the genes involved in malignant transformation: giant-cell tumors (Hammerschmidt). 2004;144:171 (This month in J Lab Clin Med)

**Glomerulonephritis**

Effects of double blockade of CD28 and inducible-costimulator signaling on anti–glomerular basement membrane glomerulonephritis (Okano et al). 2004;144:183-92

Rapidly progressive glomerulonephritis caused by anti basement-membrane antibodies: the role of T-cell activation (Hammerschmidt). 2004;144:171-2 (This month in J Lab Clin Med)

**Glutathione**

Induced sputum methodology: validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals (Beier et al). 2004;144:39-44

**Glycoproteins**

Antiphospholipid antibodies: from the trivial to the treacherous (Hammerschmidt). 2004;144:117-18 (This month in J Lab Clin Med)

Combined search for anti–ß2-glycoprotein i and anticardiolipin antibodies in antiphospholipid syndrome: contribution to diagnosis (Sanmarco et al). 2004;144:141-7

**Glycosylation**

Advanced glycation end products in urine: Are some sugar-derived products better than others? (Pamplona and Portero-Otin). 2004;144:58-9 (Editorial)

Glycation products in diabetic urine—What do they mean? (Hammerschmidt). 2004;144:57 (This month in J Lab Clin Med)

Glycosylated hemoglobin and erythrocyte survival (Hammerschmidt). 2004;144:1-2 (This month in J Lab Clin Med)

**Glycosylation end products, advanced**

Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy (Aso et al). 2004;144:92-9

H

**Health resources**

Medical decision-making and healthcare disparities: the physician's role (Aberegg and Terry). 2004;144:11-17 (Review)

Recruiting for a clinical study (disparities in health care and research) (Hammerschmidt). 2004;144:167-8 (About the cover)

**Hemodialysis;** *see* Renal dialysis

**Hemoglobin**

Advanced glycation end products in urine: Are some sugar-derived products better than others? (Pamplona and Portero-Otin). 2004;144:58-9 (Editorial)

A case of hereditary xerocytosis diagnosed as a result of suspected hypoglycemia and observed low glycohemoglobin (Jokinen et al). 2004;144:27-30

Did Ulysses have porphyria? (Pierach). 2004;144:7-10 (Review)

Glycation products in diabetic urine—What do they mean? (Hammerschmidt). 2004;144:57 (This month in J Lab Clin Med)

Glycosylated hemoglobin and erythrocyte survival (Hammerschmidt). 2004;144:1-2 (This month in J Lab Clin Med)

**Hemorrhage**

Blood group–antigen profile predicted by molecular biology in Munchausen syndrome by proxy (Montiero et al) (Letter). 2004;144:319

Sick babies, doping athletes, and Baron von Münchhausen: Whose blood is it, anyway? (Hammerschmidt). 2004;144:278 (This month in J Lab Clin Med)

**Heparin**

CT angiogram: multiple small pulmonary emboli (Hammerschmidt). 2004;144:116 (About the cover)

Dr. Jay McLean—one of the discoverers of heparin (Hammerschmidt). 2004;144:273-4 (About the cover)

Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment (Brodin et al). 2004;144:246-53

Low molecular weight heparin: a closer look at its anticoagulant effect (Hammerschmidt). 2004;144:56-7 (This month in J Lab Clin Med)

Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism (Schutgens et al). 2004;144:100-7

The newer LMW heparins: effects on the tissue-factor pathway (Hammerschmidt). 2004;144:226-7 (This month in J Lab Clin Med)

**HIV infections**

Transactivation of human immunodeficiency virus-1 in T-cells by *Mycobacterium tuberculosis*-infected mononuclear phagocytes (Toossi et al). 2004;144:108-15

Tuberculosis and HIV: mutual enhancement (Hammerschmidt). 2004;144:56 (This month in J Lab Clin Med)

**Homocysteine**

The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols (Di Guiseppe et al). 2004;144:235-46

**Hydrogen breath test**

Breath hydrogen and lactose intolerance (Hammerschmidt). 2004;144:279 (This month in J Lab Clin Med)

**Hypothyroidism**

The use of filter paper–dried blood spots for thyroid-antibody screening in adults (Hofman et al). 2004;144:307-12

I

**Ifosfamide**

Alkylators and the kidney: Why are small children more vulnerable to renal damage? (Hammerschmidt). 2004;144:278 (This month in J Lab Clin Med)

Renal ontogeny of ifosfamide nephrotoxicity (Aleksa et al). 2004; 144:285-93

**Infections**

Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and *Chlamydia pneumoniae* (Bouwman et al). 2004;144:18-26

Fungal susceptibility to zinc deprivation (Lulloff et al). 2004;144: 208-14

Mechanism(s) of fulminant liver failure (Hammerschmidt). 2004; 144:170 (This month in J Lab Clin Med)

Pathogenic molecular mechanisms in an animal model of fulminant hepatic failure: rabbit hemorrhagic viral disease (Sánchez-Campos et al). 2004;144:215-22

Secondary effects of macrolide antibiotics: Sometimes they work for the reasons we'd guess (Hammerschmidt). 2004;144:2-3 (This month in J Lab Clin Med)

Transactivation of human immunodeficiency virus-1 in T-cells by *Mycobacterium tuberculosis*-infected mononuclear phagocytes (Toossi et al). 2004;144:108-15

Tuberculosis and HIV: mutual enhancement (Hammerschmidt). 2004;144:56 (This month in J Lab Clin Med)

**Inflammation**

Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and *Chlamydia pneumoniae* (Bouwman et al). 2004;144:18-26

**Intrinsic factor**

Intrinsic factor studies: II. the effect of gastric juice on the urinary excretion of radioactivity after the oral administration of radioactive vitamin $B_{12}$ (Schilling). 2004;144:268-72 (Landmark article)

A landmark article in translational medicine Robert Schilling and intrinsic factor (Hammerschmidt). 2004;144:225-6 (This month in J Lab Clin Med)

**Iron**

Increased levels of serum transferrin receptor and serum transferrin receptor/log ferritin ratios in men with prostate cancer and the implications for body-iron stores (Kuvibidila et al). 2004;144:176-82

Iron and cancer: Is it just the liver? (Hammerschmidt). 2004;144: 169 (This month in J Lab Clin Med)

Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer (Richardson). 2004;144:173-5 (Editorial)

Is stored iron safe? (Sullivan). 2004;144:280-4 (Review)

J

***Journal of Laboratory and Clinical Medicine***

A new look and a heightened focus: translational medicine and the *Journal of Laboratory and Clinical Medicine* (Hammerschmidt). 2004;144:5-6 (Editorial)

K

**Kidney diseases;** *see also* Glomerulonephritis

Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy (Aso et al). 2004;144:92-9

**Kidneys**

Alkylators and the kidney: Why are small children more vulnerable to renal damage? (Hammerschmidt). 2004;144:278 (This month in J Lab Clin Med)

Renal ontogeny of ifosfamide nephrotoxicity (Aleksa et al). 2004; 144:285-93

L

**Lactose intolerance**

Breath hydrogen and lactose intolerance (Hammerschmidt). 2004;144:279 (This month in J Lab Clin Med)

Hydrogen breath test in the diagnosis of lactose malabsorption: Accuracy of new versus conventional criteria (Di Stefano et al). 2004;144:313-8

**Landmark articles**

Intrinsic factor studies: II. the effect of gastric juice on the urinary excretion of radioactivity after the oral administration of radioactive vitamin $B_{12}$ (Schilling). 2004;144:268-72 (Landmark article)

**Letters to the editor**

Blood group–antigen profile predicted by molecular biology in Munchausen syndrome by proxy (Montiero et al) (Letter). 2004;144:xx12

Lind's SCURVY trial (Cheng) (Letter). 2004;144:53

**Lind, James**

Lind's SCURVY trial (Cheng) (Letter). 2004;144:53

**Liver failure**

Mechanism(s) of fulminant liver failure (Hammerschmidt). 2004; 144:170 (This month in J Lab Clin Med)

Pathogenic molecular mechanisms in an animal model of fulminant hepatic failure: rabbit hemorrhagic viral disease (Sánchez-Campos et al). 2004;144:215-22

M

**McLean, Jay**

Dr. Jay McLean—one of the discoverers of heparin (Hammerschmidt). 2004;144:273-4 (About the cover)

**Munchausen syndrome**

The adventures of Freiherr von Münchhausen (Hammerschmidt). 2004;144:320-1 (About the cover)

**Munchausen syndrome by proxy**
Blood group–antigen profile predicted by molecular biology in Munchausen syndrome by proxy (Montiero et al) (Letter). 2004;144:319
Sick babies, doping athletes, and Baron von Münchhausen: Whose blood is it, anyway? (Hammerschmidt). 2004;144: 278-9 (This month in J Lab Clin Med)

**Mutation**
A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function (Casonato et al). 2004;144:254-9

**Myeloperoxidase;** *see* Peroxidases

**Myocytes, smooth muscle**
Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs (Kim et al). 2004;144:156-62
Maintaining function of vascular-access catheters: Different vascular sites may require different strategies (Hammerschmidt). 2004;144:118-19 (This month in J Lab Clin Med)

N

**Neoplasms**
Characterization of sarcomas by means of gene expression (Skubitz and Skubitz). 2004;144:78-91
Gene expression in giant-cell tumors (Skubitz et al). 2004;144: 193-200
Gene therapy: Can we make it more selective? (Hammerschmidt). 2004;144:277 (This month in J Lab Clin Med)
Generation of a human leukocyte antigen-A24–restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors (Yoshida and Tanaka). 2004;144:201-7
Homing in on the genes involved in malignant transformation: giant-cell tumors (Hammerschmidt). 2004;144:171 (This month in J Lab Clin Med)
Iron and cancer: Is it just the liver? (Hammerschmidt). 2004;144: 169 (This month in J Lab Clin Med)
Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer (Richardson). 2004;144:173-5 (Editorial)
Is stored iron safe? (Sullivan). 2004;144:280-4 (Review)

**Neutrophils**
Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good (Meyer). 2004;144:124-6 (Editorial)
Peroxidase activity within circulating neutrophils correlates with pulmonary phenotype in cystic fibrosis (Garner). 2004;144: 127-33

**Nitric oxide**
Nitric oxide acts on the mitochondria and protects human endothelial cells from apoptosis (Hida et al). 2004;144:148-55
Rheumatoid pannus: What is nitric oxide doing there? (Hammerschmidt). 2004;144:119-20 (This month in J Lab Clin Med)

O

**Osteopetrosis**
Donald G. Walker, MD: parabiosis and the pathobiology of osteopetrosis (Hammerschmidt). 2004;144:223-4 (About the cover)

**Osteoporosis**
Osteoclast enzymes and bone density: Can serum assays provide useful clinical information? (Hammerschmidt). 2004;144:118 (This month in J Lab Clin Med)
Soluble cathepsin-L: a marker of bone resorption and bone density? (Lang et al). 2004;144:163-6

**Oxalates**
Serum oxalate in human beings and rats as determined with the use of ion chromatography (Harris et al). 2004;144:45-52

**Oxidative stress**
Induced sputum methodology: validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals (Beier et al). 2004;144:39-44

P

**Parabiosis**
Donald G. Walker, MD: parabiosis and the pathobiology of osteopetrosis (Hammerschmidt). 2004;144:223-4 (About the cover)

**Peroxidases**
Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good (Meyer). 2004;144:124-6 (Editorial)
Peroxidase activity within circulating neutrophils correlates with pulmonary phenotype in cystic fibrosis (Garner). 2004;144: 127-33

**Plasminogen activator inhibitor 1**
Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting–enzyme inhibitor (Kenichi et al). 2004;144:69-77

**Platelets**
A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function (Casonato et al). 2004;144:254-9
The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease (Hara et al). 2004;144:31-7

**Polymorphisms**
Mutations in the gene encoding cytosolic β-glucosidase in Gaucher disease (Beutler et al). 2004;144:65-8

**Porphyria**
Did Ulysses have porphyria? (Pierach). 2004;144:7-10 (Review)

**Prostatic neoplasms**
Increased levels of serum transferrin receptor and serum transferrin receptor/log ferritin ratios in men with prostate cancer and the implications for body-iron stores (Kuvibidila et al). 2004;144:176-82
Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer (Richardson). 2004;144:173-5 (Editorial)

**Pulmonary embolism**
CT angiogram: multiple small pulmonary emboli (Hammerschmidt). 2004;144:116 (About the cover)
Low molecular weight heparin: a closer look at its anticoagulant effect (Hammerschmidt). 2004;144:56-7 (This month in J Lab Clin Med)
Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism (Schutgens et al). 2004;144:100-7

R

**Receptors, transferrin**
Increased levels of serum transferrin receptor and serum transferrin receptor/log ferritin ratios in men with prostate cancer and the implications for body-iron stores (Kuvibidila et al). 2004;144:176-82
Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer (Richardson). 2004;144:173-5 (Editorial)

**Renal dialysis**
Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs (Kim et al). 2004;144:156-62

**Research**
Challenges in translational medicine: the changing face of research ethics (Hammerschmidt). 2004;144:226 (This month in J Lab Clin Med)
Ethical issues in the collection, storage, and research use of human biological materials (Meslin and Quaid). 2004;144:229-34 (Review)
A new look and a heightened focus: translational medicine and the *Journal of Laboratory and Clinical Medicine* (Hammerschmidt). 2004;144:5-6 (Editorial)
Recruiting for a clinical study (disparities in health care and research) (Hammerschmidt). 2004;144:167-8 (About the cover)

**Review articles**
On the challenges of using evidence-based information: the role of clinical uncertainty (Ghosh). 2004;144:60-4 (Review)
Did Ulysses have porphyria? (Pierach). 2004;144:7-10 (Review)
Ethical issues in the collection, storage, and research use of human biological materials (Meslin and Quaid). 2004;144:229-34 (Review)
Is stored iron safe? (Sullivan). 2004;144:280-4 (Review)
Medical decision-making and healthcare disparities: the physician's role (Aberegg and Terry). 2004;144:11-17 (Review)

S

**Sarcomas**
Characterization of sarcomas by means of gene expression (Skubitz and Skubitz). 2004;144:78-91

**Scurvy**
Lind's SCURVY trial (Cheng) (Letter). 2004;144:53

***Serotonin***
The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease (Hara et al). 2004;144:31-7
Serotonin profile in the blood: Might it be a useful marker of vascular disease? (Hammerschmidt). 2004;144:2 (This month in J Lab Clin Med)

**Sports**
Sick babies, doping athletes, and Baron von Münchhausen: Whose blood is it, anyway? (Hammerschmidt). 2004;144:278-9 (This month in J Lab Clin Med)

**Sulfhydryl compounds**
The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols (Di Guiseppe et al). 2004;144:235-46

T

**T-lymphocytes**
Effects of double blockade of CD28 and inducible-costimulator signaling on anti–glomerular basement membrane glomerulonephritis (Okano et al). 2004;144:183-92
Generation of a human leukocyte antigen-A24–restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors (Yoshida and Tanaka). 2004;144:201-7
Rapidly progressive glomerulonephritis caused by anti basement-membrane antibodies: the role of T-cell activation (Hammerschmidt). 2004;144:171-2 (This month in J Lab Clin Med)

**Telomerase reverse transcriptase**
Tumor-specific expression detected with the use of an expression vector driven by human telomerase reverse transcriptase gene promoter (Yin et al). 2004;144:302-6

**Thyroid diseases**
The use of filter paper–dried blood spots for thyroid-antibody screening in adults (Hofman et al). 2004;144:307-12

**Tissue-factor-pathway inhibitor**
Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment (Brodin et al). 2004;144:246-53
The newer LMW heparins: effects on the tissue-factor pathway (Hammerschmidt). 2004;144:226-7 (This month in J Lab Clin Med)

**Transferrin receptors;** *see* Receptors, transferrin

**Translational medicine**
Challenges in translational medicine: the changing face of research ethics (Hammerschmidt). 2004;144:226 (This month in J Lab Clin Med)
Evidence-based medicine: What do you do when the evidence is lacking? An essay in translational medicine (Hammerschmidt). 2004;144:55-6 (This month in J Lab Clin Med)
A landmark article in translational medicine Robert Schilling and intrinsic factor (Hammerschmidt). 2004;144:225-6 (This month in J Lab Clin Med)
A new look and a heightened focus: translational medicine and the *Journal of Laboratory and Clinical Medicine* (Hammerschmidt). 2004;144:5-6 (Editorial)

***Tuberculosis***
Transactivation of human immunodeficiency virus-1 in T-cells by *Mycobacterium tuberculosis*-infected mononuclear phagocytes (Toossi et al). 2004;144:108-15
Tuberculosis and HIV: mutual enhancement (Hammerschmidt). 2004;144:56 (This month in J Lab Clin Med)

U

***"Ulysses syndrome"***
Did Ulysses have porphyria? (Pierach). 2004;144:7-10 (Review)
Odysseus and the sirens (Hammerschmidt). 2004;144:54 (About the cover)

**Urinary Plasminogen Activator**
Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor (Kenichi et al). 2004;144:69-77

V

**Vascular diseases**
Serotonin profile in the blood: Might it be a useful marker of vascular disease? (Hammerschmidt). 2004;144:2 (This month in J Lab Clin Med)

**Virus diseases**
Pathogenic molecular mechanisms in an animal model of fulminant hepatic failure: rabbit hemorrhagic viral disease (Sánchez-Campos et al). 2004;144:215-22

**Vitamin B 12**
Intrinsic factor studies: II. the effect of gastric juice on the urinary excretion of radioactivity after the oral administration of radioactive vitamin $B_{12}$ (Schilling). 2004;144:268-72 (Landmark article)
A landmark article in translational medicine Robert Schilling and intrinsic factor (Hammerschmidt). 2004;144:225-6 (This month in J Lab Clin Med)

**von Willebrand factor**
A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function (Casonato et al). 2004;144:254-9

W

**Walker, Donald G.**
Donald G. Walker, MD: parabiosis and the pathobiology of osteopetrosis (Hammerschmidt). 2004;144:223-4 (About the cover)

**Wilson's disease**
Measuring ceruloplasmin (Hammerschmidt). 2004;144:279 (This month in J Lab Clin Med)
Value of an enzymatic assay for the determination of serum ceruloplasmin (MacIntyre et al). 2004;144:294-301

Z

**Zinc**
Fungal susceptibility to zinc deprivation (Lulloff et al). 2004;144:208-14
Metallic cations and fungal growth (Hammerschmidt). 2004;144:170 (This month in J Lab Clin Med)